NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
company developing a pipeline of selective oral immunology
therapies focused on treating chronic inflammatory and autoimmune
diseases, today announced participation in the following investor
and scientific conferences in September:
- September 13-15: H.C.
Wainwright 23rd Annual Global Investment Conference.
Daniel Vitt, Ph.D., Chief Executive
Officer and President of Immunic, will present a company overview
at the conference. The on-demand presentation will be available for
viewing beginning September 13, at
7:00 am ET. An audio webcast of the
presentation will be available on the "Events and Presentations"
section of Immunic's website at:
ir.imux.com/events-and-presentations. An archived replay will be
available on the company's website for a period of 90 days after
the conference.
- September 22-25:
50th Annual European Society for Dermatological
Research (ESDR) Meeting. Irina Betscheider, Ph.D., Clinical
Operations Program Lead at Immunic, will present the first clinical
experience with IMU-935, an orally available, selective inverse
agonist of RORγt. The poster presentation will be accessible on the
"Events and Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations.
-
- Poster Number: ESDR057
- Title: Safety, tolerability and pharmacokinetics of single
and multiple oral doses of IMU-935 in healthy volunteers: First
clinical experience with an orally available small molecule
inhibitor of IL-17
- September 27-30: 2021
Cantor Virtual Global Healthcare Conference. Dr. Vitt will
participate in a fireside chat on Tuesday, September 28, at 10:00 am ET. A live audio webcast of the
presentation will be available on the "Events and Presentations"
section of Immunic's website
at: ir.imux.com/events-and-presentations. An archived replay
will be available on the company's website for a period of 90
days.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
clinical-stage biopharmaceutical company with a pipeline of
selective oral immunology therapies focused on treating chronic
inflammatory and autoimmune diseases. The company is developing
three small molecule products: its lead development program,
IMU-838, a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH and exhibits a host-based antiviral effect, is
currently being developed as a treatment option for multiple
sclerosis, ulcerative colitis, Crohn's disease, and primary
sclerosing cholangitis. IMU-935, a selective inverse agonist of the
transcription factor RORγt, is targeted for development in
psoriasis, castration-resistant prostate cancer and Guillain-Barré
syndrome. IMU-856, which targets the restoration of the intestinal
barrier function, is targeted for development in diseases involving
bowel barrier dysfunction. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's participation in investor and scientific conferences.
Immunic may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient resources to meet business objectives
and operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by
Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be
found in the section captioned "Risk Factors," in the company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on
February 26, 2021, and in the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this
release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic expressly
disclaims all liability in respect to actions taken or not taken
based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september-301370253.html
SOURCE Immunic, Inc.